What is the role of injectable, sustained-release naltrexone (Depotrex) for opioid abuse relapse prevention?

Updated: Jun 21, 2018
  • Author: David W Dixon, DO; Chief Editor: Glen L Xiong, MD  more...
  • Print

A randomized, placebo-controlled trial suggested that an injectable, sustained-release form of naltrexone (Depotrex) increased retention of patients in treatment for opioid abuse. [50] Further studies are necessary to evaluate the efficacy of this treatment modality.

FDA approval of extended-release IM naltrexone for the prevention of relapse to opioid dependence was based on data from a 6-month, multicenter, randomized, phase 3 study, which met its primary efficacy endpoint and all secondary efficacy endpoints. Once monthly treatment with extended-release IM naltrexone showed statistically significant higher rates of opioid-free urine screens compared with placebo (P< .0002).

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!